Roundup's Last Stand: Bayer Bought the Liability Too

€10 billion. That's roughly what Bayer has paid out, set aside, or negotiated away in Roundup settlements since it acquired Monsanto in 2018 for €63 billion and inherited a litigation portfolio that would have made any competent due diligence lawyer resign on the spot. Thursday's U.S. Supreme Court ruling has now handed Bayer something it hasn't had in years: breathing room. The question worth asking isn't whether Bayer wins. It's who decided the price of winning was acceptable before the deal closed — and what they knew when they decided it.

Let me explain what actually happened, because the headlines are doing the law a disservice.

The Supreme Court's ruling doesn't say Roundup is safe. It doesn't say plaintiffs were lying. What it does — and this is the move that matters — is raise the federal preemption bar high enough that many state tort claims become structurally difficult to pursue. When federal regulatory approval covers a product's labeling, and a plaintiff argues that label should have said something different, the question becomes whether state law can impose a higher warning standard than the federal agency required. The Court, on Thursday, said largely no. That's preemption. It's not a finding of fact. It's a jurisdictional ceiling — and it's the kind of ceiling that corporate defendants spend years and millions building toward, one amicus brief at a time.

Tens of thousands of cases are now in varying degrees of jeopardy. Some will survive — the plaintiffs' bar is already identifying the angles: claims that don't turn on label adequacy, claims tied to specific conduct rather than regulatory compliance, arguments that the federal approval process was itself corrupted by industry influence. That last one is the interesting play. If you can show the regulator was captured, preemption loses its moral authority even if it retains its legal force. It's a harder case to make, but it's the one I'd be working on if I were sitting across from a Bayer partner right now.

Here's what this ruling actually teaches, and it applies whether you're a farmworker in Louisiana or a small supplier anywhere in the EU supply chain: the contract, the label, and the regulatory filing are not the ceiling of a company's obligation — they are its floor. The legal industry has spent forty years teaching corporations to engineer their floor as high as possible so that everything above it looks like grace. Monsanto built a floor. Bayer walked in, looked at it, and wrote the cheque anyway.

For Maltese and EU readers, the preemption doctrine doesn't translate directly — the EU operates differently, with directives setting minimum standards that member states can exceed, not federal ceilings that they cannot. But the underlying mechanic is identical in practice: large product manufacturers use regulatory compliance as a shield in litigation. You see it in pharmaceutical cases before the CJEU. You see it in product liability disputes under Directive 85/374/EEC. The argument is always the same: *we followed the rules, therefore we cannot be negligent.* The counter-argument, which European courts have been more willing to entertain than their American counterparts, is that following minimum rules is not the same as exercising reasonable care. That gap — between compliance and care — is where the real cases live.

The data protection due diligence materials published this week by Thomson Reuters Legal are a quiet reminder of the same principle operating in a different field. A checklist for GDPR due diligence in M&A transactions sounds administrative. What it actually is: a map of where the liability is buried before you sign. Bayer had lawyers. Bayer had due diligence. What Bayer apparently didn't have was someone willing to tell the board that the litigation dossier they were inheriting wasn't a line item — it was a business model they were buying into. Due diligence is only worth what you're willing to hear.

I spent years before the suits running with people who read contracts the way civilians read menus — looking for the good parts, skipping the fine print. The fine print is where the real terms live. Always.

The plaintiffs' bar calling Thursday's ruling "overdue justice" for Monsanto is doing something rhetorically interesting — they're framing a defendant's win as somehow settling a moral account. It isn't. What it is, is a reminder that the best moment to fight a corporate product liability case is before the product is approved, not after ten thousand people have filed claims. Regulatory capture is